Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective is to investigate the long-term safety and tolerability of NN1250. This is done by comparing NN1250 to insulin glargine after 104 weeks of treatment (52 weeks of treatment in NN1250-3579 plus 52 weeks of treatment in this extension trial) in terms of the listed safety assessments from which endpoints will be calculated: • Adverse events • Hypoglycaemic episodes • Clinical evaluation • Laboratory assessments • Body weight • Insulin dose
Inclusion criteria
- Type 2 Diabetes